Aaron Mansfield (@amansfieldmd) 's Twitter Profile
Aaron Mansfield

@amansfieldmd

Thoracic oncologist at Mayo Clinic. Tweets my own.

ID: 4828058460

calendar_today29-01-2016 01:24:05

518 Tweet

1,1K Takipçi

1,1K Takip Edilen

Journal for ImmunoTherapy of Cancer (@jitcancer) 's Twitter Profile Photo

Tweetorial: Let's take a closer look at the recently-published article from Desai et al - "Dynamics and survival associations of T cell receptor clusters in patients with pleural #mesothelioma treated with #immunotherapy" Read the full article here: bit.ly/3NislPU 1/7

Tweetorial: Let's take a closer look at the recently-published article from Desai et al - "Dynamics and survival associations of T cell receptor clusters in patients with pleural #mesothelioma treated with #immunotherapy" 
Read the full article here: bit.ly/3NislPU 1/7
IASLC (@iaslc) 's Twitter Profile Photo

Head down to Chicago Ballroom E at #NACLC23 now to hear Aaron Mansfield provide a status update of NRG-LU006, review the role of surgery following results of the MARS2 trial, and consider the use of PD-1/CTLA-4 inhibition following results of the IND.227 trial. Mayo Clinic

Head down to Chicago Ballroom E at #NACLC23 now to hear <a href="/AMansfieldMD/">Aaron Mansfield</a> provide a status update of NRG-LU006, review the role of surgery following results of the MARS2 trial, and consider the use of PD-1/CTLA-4 inhibition following results of the IND.227 trial. <a href="/MayoClinic/">Mayo Clinic</a>
Mayo Clinic Center for Individualized Medicine (@mayocliniccim) 's Twitter Profile Photo

Even the most advanced cancer therapies can’t work if tumors don’t absorb them. Mayo Clinic researchers, led by Aaron Mansfield, are pioneering a strategy to help targeted treatments get inside cancer cells. Discover more: mayocl.in/3WD9N24

Jake Orme MD PhD (@jakeormemdphd) 's Twitter Profile Photo

So grateful to the brave patients and their families that made this clinical trial possible, an entirely new way to restore sensitivity to immunotherapy using plasma exchange. Mayo Clinic Mayo Clinic Comprehensive Cancer Center Fabrice Lucien, PhD Nat Comm rdcu.be/edrKN

Joshua Reuss (@joshua_reuss) 's Twitter Profile Photo

Insightful discussion on rare thoracic malignancies - thymoma/thymic carcinoma & mesothelioma at #TexasLung25. Challenging malignancies to diagnose and treat, often requiring sub-specialty and multi-d input.

Insightful discussion on rare thoracic malignancies - thymoma/thymic carcinoma &amp; mesothelioma at #TexasLung25. Challenging malignancies to diagnose and treat, often requiring sub-specialty and multi-d input.
Dipesh Uprety MD FACP (@dipeshupretymd) 's Twitter Profile Photo

Dear IASLC members, I am proud to support Dr. Adjei's nomination for the IASLC President-an outstanding mentor, a passionate patient advocate, a lifelong teacher, exceptional clinician and truly remarkable human being. Please join me in supporting his candidacy #LCSM OncoAlert

Dear <a href="/IASLC/">IASLC</a> members,
I am proud to support Dr. Adjei's nomination for the IASLC President-an outstanding mentor, a passionate patient advocate, a lifelong teacher, exceptional clinician and truly remarkable human being. Please join me in supporting his candidacy #LCSM <a href="/OncoAlert/">OncoAlert</a>
Aaron Mansfield (@amansfieldmd) 's Twitter Profile Photo

Congratulations Kaushal! I’m proud of you. It is wonderful to see all of your hard work being recognized with this opportunity. Thank you Aadel Chaudhuri, MD PhD for your co-mentorship!

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Congratulations to Dr. Yongchang Zhang and his prospective phase III trial showing the impact of time of infusion on survival with immunotherapy in NSCLC. A no cost intervention that can have a huge impact. One of the top #ASCO25 presentations for me this year.

Congratulations to Dr. <a href="/zhang_yongchang/">Yongchang Zhang</a> and his prospective phase III trial showing the impact of time of infusion on survival with immunotherapy in NSCLC. A no cost intervention that can have a huge impact. One of the top #ASCO25 presentations for me this year.